Harmon Cyrus's Form 4 filing
Olema Pharmaceuticals, Inc. (OLMA) · filed Jul 27, 2026
- Accession no.
- 0001831410-26-000008
- Filed
- Jul 27, 2026, 7:30 PM ET
- Trade date
- Jul 23-24, 2026
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market sales total $291.2K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Harmon CyrusCIK 0001831410 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The weighted average sale price for the transaction reported was $11.579, and the range of prices were between $11.52 and $11.675. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
Referenced by the price of 1 transaction in Table I.
- F2
The weighted average sale price for the transaction reported was $11.714, and the range of prices were between $11.70 and $11.775. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
Referenced by the price of 1 transaction in Table I.